| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 92.1 | 51.3 |
| Profit before tax | -40.8 | -52.8 |
| Net income | -41.4 | -52.9 |
| EPS (diluted, $ a share) | $-0.61 | $-0.82 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +79.6% |
|---|---|
| Operating margin | -42.6% |
10-Q filed with the SEC, NASDAQ: RYTM. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Rhythm Pharmaceuticals, Inc.: key numbers
- Share price
- $107.48Close, Nov 16
- Market cap
- $7.45B
- Shares outstanding
- 69.33MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Rhythm Pharmaceuticals, Inc.
All →Rhythm Pharmaceuticals Financial Results
Rhythm Pharmaceuticals reported Q3 2026 net product revenue of $92.1 million, a 29% sequential increase driven by the strong U.S. launch of IMCIVREE for acquired hypothalamic obesity. The company also secured a five-year term loan facility for up to $750 million and announced plans to advance bivamelagon into pivotal development for Prader-Willi syndrome.
- Term
- Q3 2026
“Rhythm continues to make strong progress in bringing IMCIVREE® (setmelanotide) to patients with acquired hypothalamic obesity (HO), highlighted by continued commercial momentum in the United States. Our commercial launch in Japan represents another important milestone in a market with the potential to become our second largest.”
David Meeker, M.D., Chairman, Chief Executive Officer and President of Rhythm Pharmaceuticals
“We are excited about advancing our next-generation MC4R agonists, beginning with bivamelagon. Strong clinical results have reinforced our confidence in its potential across multiple indications, and we look forward to initiating pivotal trials in acquired HO and Prader-Willi syndrome.”
David Meeker, M.D., Chairman, Chief Executive Officer and President of Rhythm Pharmaceuticals